Is pulse dosing of terbinafine more effective than continuous daily dosing for dermatophyte onychomycosis?

Is Pulse Dose Terbinafine More Effective Than Daily Dosing?

No, continuous daily terbinafine is superior to pulse dosing for dermatophyte onychomycosis and should be used as the standard regimen. 1, 2

Evidence-Based Recommendation

The British Association of Dermatologists explicitly recommends terbinafine 250 mg once daily for 12 weeks for toenail onychomycosis and 6 weeks for fingernail onychomycosis as the gold-standard first-line treatment, with no endorsement of pulse dosing regimens. 1, 3

Why Continuous Dosing is Superior

Continuous daily terbinafine achieves significantly higher cure rates across all outcome measures:

• Mycological cure of target toenail: 70.9% (continuous) vs 58.7% (pulse), with a relative risk of 1.21 (95% CI 1.02-1.43, P=0.03) 2
• Clinical cure of target toenail: 44.6% (continuous) vs 29.3% (pulse), with a relative risk of 1.52 (95% CI 1.11-2.07, P=0.007) 2
• Complete cure of target toenail: 40.5% (continuous) vs 28.0% (pulse), with a relative risk of 1.45 (95% CI 1.04-2.01, P=0.02) 2
• Complete cure of all 10 toenails: 25.2% (continuous) vs 14.7% (pulse), with a relative risk of 1.71 (95% CI 1.05-2.79, P=0.03) 2

Guideline Position on Pulse Dosing

The British Association of Dermatologists guidelines acknowledge that pulse regimens were developed for itraconazole—not terbinafine—based on the pharmacokinetic property of prolonged nail persistence. 1 While itraconazole is licensed for pulse therapy (400 mg daily for 1 week per month), terbinafine is licensed only for continuous daily dosing. 1, 3

The 2014 British guidelines state that "continuous daily dosing of terbinafine yields superior outcomes compared with intermittent or pulse regimens." 4

Conflicting Research Evidence

While the highest-quality guideline evidence and the largest randomized controlled trial 2 demonstrate continuous dosing superiority, some smaller studies have reported conflicting findings:

• A 2015 Indian study (n=76) found no significant difference between continuous and pulse regimens, though it acknowledged that short follow-up may have led to lower recorded cure rates. 5
• A 2009 Japanese study (n=55) reported 74.5% complete cure with pulse therapy combined with topical terbinafine, but this was an uncontrolled study without a continuous-dosing comparator. 6
• A 2020 network meta-analysis found no significant difference between continuous and pulse regimens, but this pooled heterogeneous studies with varying definitions of cure and follow-up periods. 7

However, a 2023 study (n=60) strongly reinforced the superiority of continuous dosing, showing 76.67% efficacy with continuous therapy versus only 26.67% with pulse therapy. 8

Clinical Algorithm

For dermatophyte toenail onychomycosis:

1. Confirm diagnosis with both microscopy and culture before prescribing. 1, 3
2. Obtain baseline liver function tests (ALT, AST) and complete blood count. 1, 3
3. Prescribe terbinafine 250 mg once daily for 12 weeks (extend to 16 weeks for severe infections). 1, 3
4. Re-evaluate at 3-6 months with mycological analysis and clinical examination. 1, 3
5. If treatment fails, restart terbinafine 250 mg daily for the full 12-week course. 3
6. If second course fails, switch to itraconazole 200 mg daily for 12 weeks or 400 mg daily for 1 week per month for 3 cycles. 3, 4

For fingernail onychomycosis:

• Terbinafine 250 mg once daily for 6 weeks. 1, 3

Critical Safety Considerations

Tolerability does not differ between continuous and pulse regimens (chi-square=1.63, P=0.65), so safety concerns do not justify choosing pulse therapy. 2

Absolute contraindications to terbinafine:

• Active or chronic liver disease 1, 3
• Lupus erythematosus 9

Common adverse effects (occur in 49% gastrointestinal, 23% dermatological) include nausea, diarrhea, taste disturbance, rash, and headache, with serious adverse events occurring in only 0.04% of patients. 1, 3

Why Pulse Dosing Fails

Terbinafine's pharmacokinetics do support nail persistence (detectable for 6 months post-treatment), but this does not translate to equivalent efficacy with pulse dosing. 1, 9 The fungicidal mechanism requires sustained drug concentrations to achieve the very low minimum inhibitory concentration (0.004 μg/mL) necessary for dermatophyte eradication. 1

Pulse dosing was developed for itraconazole, not terbinafine, and extrapolating this approach to terbinafine lacks evidence-based support. 1

Cost-Effectiveness Caveat

While pulse regimens may appear more cost-effective due to reduced total drug consumption, the significantly lower cure rates result in higher treatment failure rates, necessitating repeat courses or alternative therapies that ultimately increase total healthcare costs. 2, 8 The 2005 Veterans Affairs study specifically noted that "this expensive therapy [was] much less effective than previously believed" when using pulse dosing. 2